INTRODUCTION {#s1}
============

Melanoma Frequency in the World {#s2}
-------------------------------

Melanoma is the second most common skin cancer and the most aggressive. Prevalence records have shown that the highest rates are in Australia (39 cases per 100,000 inhabitants per year) and New Zealand (34 cases per 100,000 inhabitants), followed by the United States with 17 cases per 100,000 inhabitants.^[@B1],[@B2]^ As known, melanoma rates are higher among people with fair skin with European descent and considerably lower in those with darker skin (eg, Hispanics and blacks in the United States).^[@B3]^ Other European populations (eg, those in Great Britain, Germany, the Netherlands, Austria, and France) report rates of four to 10 cases per 100,000 inhabitants. African, Asian, and Pacific non-Caucasian populations report lower rates of three per 100,000 inhabitants.^[@B2]^

In Latin America, a prevalence of 1.7 cases per 100,000 inhabitants is estimated by the International Agency for Research on Cancer, with an extensive variability of zero cases per 100,000 in countries such as Belize to 7.6 cases per 100,000 in Uruguay.^[@B1]^ In Mexico, the actual prevalence of malignant melanoma is unknown; estimations are two cases per 100,000 inhabitants according to International Agency for Research on Cancer^[@B1]^; however, national reports in hospital records report a lower incidence of 0.4 cases per 100,000^[@B4]^ to 1.01 cases per 100,000 inhabitants, according to a retrospective study from the Malignant Neoplasm Histopathological Record.^[@B5]^

*BRAF* Mutation {#s3}
---------------

The *BRAF* gene (v-raf murine sarcoma viral oncogene homolog B1; Mendelian Inheritance of Man no. 164757) is located at the 7q34 chromosome and encodes a serine/threonine kinase proto-oncogene, the normal function of which is to control the proliferation and differentiation through the mitogen-activated protein kinase pathway.

In general, mutations in *BRAF* may be found in 8% of human cancers, including 50% of melanomas, 30% to 70% of thyroid cancers, 30% of low-grade ovarian cancer, and 10% of colorectal cancer.^[@B6]^ In the article by Davies et al^[@B7]^, somatic mutations in the BRAF gene were found in 66% of malignant melanomas, of which 80% corresponded to a simple substitution of a neutral amino acid (valine at position 599 in exon 15) by one negatively charged by glutamic acid. Subsequently, this numeric sequence was changed by V600E because of a discrepancy of a codon in exon 1 of the *BRAF* genetic sequence.^[@B8]^

The number of reports of *BRAF* mutations in primary malignant and metastatic melanoma has grown. On average, constitutive mutations in the *BRAF* oncogene are reported in 33% to 47% of primary melanomas and 41% to 55% of metastatic melanomas. V600E mutations have been described in different populations, especially Caucasian, European, and Asian populations.^[@B9]-[@B14]^ In this article, we report our experience in V600E mutation and its clinical significance in the Mexican population.

PATIENTS AND METHOD {#s4}
===================

Patients and Tumor Tissue Samples {#s5}
---------------------------------

Tumor tissue samples were collected from different oncology centers throughout Mexico. From May 2012 to March 2013, 146 patients diagnosed with melanoma (metastatic or recurrent) were included in the study. Each patient signed an informed consent endorsed by the national institute authorities. Initially, only information about age, sex, histologic subtype, and clinical stage was requested. Afterward, information regarding ulceration degree; sites of metastasis; and treatment received, such as surgery, systemic therapy, and/or radiotherapy, was requested via e-mail. From the 146 samples, 139 could be analyzed for *BRAF* V600E mutation. From this cohort, 11 samples were excluded because of rare subtypes.

DNA Preparation and Mutation Test {#s6}
---------------------------------

Genomic DNA was extracted from paraffin-embedded tissue samples by using the QIAamp DNA FFPE Tissue Kit (catalog no. 56404; Qiagen, Hilden, Germany). For the detection of the mutation, we followed the instructions for and used the cobas 4800 *BRAF* V600 mutation test kit (Roche Molecular Systems, Pleasanton, CA), a real-time polymerase chain reaction-based assay designed to detect the presence of *BRAF* V600E (1799T\>A).

Statistical Analysis {#s7}
--------------------

All statistical analyses were performed using software SPSS version 23 (IBM, Armonk, NY). Categorical information was described using frequencies and percentages. The continuous information such as age was described by using mean ± standard deviation or mean (range) for information with normal distribution. The χ^2^ test or Fisher\'s exact test was used to differentiate the rates of different groups, and the differences in measurements of two groups were assessed through an unpaired *t* test.

RESULTS {#s8}
=======

*BRAF* V600E Gene Mutations in Melanoma {#s9}
---------------------------------------

A total of 127 patients with melanoma were included in the study; their cancer was classified according to the American Joint Committee on Cancer as stage IIIB (n = 16), stage IIIC (n = 24), stage IV (n = 58), and unclassified (n = 29). The frequency of somatic mutation V600E in the *BRAF* gene was 54.6% (43 of 127 patients). The analysis of *BRAF* was performed in tumor tissue that was used for the initial pathologic diagnosis.

A descriptive analysis per geographical region of Mexico was performed; more samples were collected in the northern and central regions of the country. The central regions of Mexico focus more attention on melanoma, and these regions contributed more samples. More mutations per case were recorded in samples from the northwest region (12 of 25 samples).

Clinical Characteristics Related to *BRAF* V600E Mutation {#s10}
---------------------------------------------------------

The clinicopathologic characteristics of the tumor samples and their relationship with the mutational stage are summarized in [Table 1](#T1){ref-type="table"}. The *BRAF* V600E mutation was more frequent in patients 40 to 60 years of age, compared with those younger than 40 and older than 60 years (*P* = .012). There was no association between sex and *BRAF* V600E mutation.

###### 

Clinical and Pathologic Characteristics

![](JGO.2016.008912t1)

When histologic subtypes were compared, the prevalence of *BRAF* V600E differed from that reported in other series.^[@B15]^ In our population, the superficial spreading melanoma presented a lower mutation frequency in comparison with that of nodular melanoma (18.6% *v* 37.2%, respectively); lentigo maligna melanoma and acral lentiginous melanoma (the other two subtypes) had mutation frequencies of 9.3% and 6.9%, respectively.

Up to 44% of patients had melanoma located on the lower limbs and only one patient (10%) had the *BRAF* V600E mutation. In 25 patients, previous sun exposure could be determined, showing a similar tendency to that reported in literature in which nonexposed patients had two cases of mutations compared with one case of mutation in those with sun exposure.

Prognostic Significance of *BRAF* V600E Mutation {#s11}
------------------------------------------------

Overall survival data were obtained from only 25 patients. The median follow-up was 9.38 months (range, 3.6 to 21.4 months). The median overall survival time for patients with mutated *BRAF* was 6.5 months, compared with 13.1 months for patients with wild-type *BRAF* (*P* = .174). Other analyses were difficult to perform because of the size of the sample and the lack of clinicopathologic information.

DISCUSSION {#s12}
==========

Malignant melanoma in Mexico has an estimated prevalence of 1.2%,^[@B5]^ but the real prevalence is unknown. This study aimed to determine the frequency of *BRAF* V600E mutations in a heterogeneous population of Mexican patients with malignant melanoma. The result shows a mean frequency of 54.6%, similar to that reported in the Caucasian and European populations, differing from Asian and South American populations. [Table 2](#T2){ref-type="table"} lists evidence of the prevalence of *BRAF* mutation in different countries.

###### 

Prevalence of *BRAF* Mutation in Different Countries

![](JGO.2016.008912t2)

In Mexican patients, two previous studies searching for *BRAF* V600E mutations found a distant frequency, from 6.4%^[@B24]^ to 73%,^[@B25]^ explained by the heterogeneity of the populations analyzed (from the center and northeast of the country, respectively) and the size of the sample analyzed (\< 50 patients). The current study shows the correlation of the mutation with clinical characteristics is similar to those in other populations,^[@B15]^ although it was not feasible to perform a deeper analysis because of incomplete clinical information. The most frequent histologic subtype in the Mexican population is acral lentiginous melanoma^[@B26]^; however, nodular melanoma is the form with the highest number of cases with *BRAF* V600E mutations, consistent with that reported in a previous study.^[@B25]^ In the present cohort, no mucous melanoma cases or *BRAF* mutation were reported. One of the lines of research of our group, however, has been characterizing melanomas in sinunasal and buccal mucosa in the Mexican population,^[@B27]^ and we have found a lower distribution than that reported in skin lesions (data not shown). In our study, the central part of the country was the region with the highest prevalence of *BRAF* mutation (41.8%), as observed in a previous study.^[@B24]^ This might be related to the sample supply and the general ethnic mix in the country. In Mexico, larger epidemiologic and educational efforts are needed to determine the current incidence of melanoma, as are better data collection tools and definition of the characteristics of the different regions of the country to perform better studies of clinicopathologic correlation.

The quantitative polymerase chain reaction thermal cycler (CobasZ480) was provided by Roche Mexico.
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